Proton magnetic resonance spectroscopic imaging studies in patients with newly diagnosed partial epilepsy

Epilepsia

Volumn 41, Issue 7, 2000, Pages 825-831

  Li, Li Min ^a   Dubeau, François ^a   Andermann, Frederick ^a   Arnold, Douglas L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Epilepsy; MRS; Neuronal recovery; Newly diagnosed epilepsy

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE;

EID: 0033934188     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00249.x     Document Type: Article

References (56)

1. Gadian DG. N-acetylaspartate and epilepsy. Magn Reson Imaging 1995;13:1193-5.
2. Knizley H Jr. The enzymatic synthesis of N-acetyl-L-aspartic acid by a water-insoluble preparation of a cat brain acetone powder. J Biol Chem 1967;242:4619-22.
3. Goldstein FB. The enzymatic synthesis of N-acetyl-L-aspartic acid by subcellular preparations of rat brain. J Biol Chem 1969;244: 4257-60.
4. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979;184:539-46.
5. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991:2:131-4.
6. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acelyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
7. Guimaraes AR, Schwartz P, Prakash MR, et al. Quantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience 1995;69:1095-1101.
8. Strauss I, Williamson JM, Bertram EH, Lothman EW, Fernandez EJ. Histological and 1H magnetic resonance spectroscopic imaging analysis of quinolinic acid-induced damage to the rat striatum. Magn Reson Med 1997;37:24-33.
9. Najm IM, Wang Y, Shedid D. Luders HO, Ng TC, Comair YG. MRS metabolic markers of seizures and seizure-induced neuronal damage. Epilepsia 1998;39:244-50.
10. Ebisu T, Rooney WD, Graham SH, Weiner MW, Maudsley AA. N-acetylaspartate as an in vivo marker of neuronal viability in kainate-induced status epilepticus: 1H magnetic resonance spectroscopic imaging. J Cereb Blood Flow Metab 1994;14:373-82.
11. Pioro EP, Wang Y, Moore JK, et al. Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. Neuroreport 1998; 9:3041-6.
12. Nakano M, Ueda H, Li JY, Matsumoto M, Yanagihara T. Measurement of regional N-acetylaspartate after transient global ischemia in gerbils with and without ischemic tolerance: an index of neuronal survival. Ann Neurol 1998;44:334-40.
13. Moller HE, Vermathen P, Lentschig MG, et al. Metabolic characterization of AIDS dementia complex by spectroscopic imaging. J Magn Reson Imaging 1999;9:10-8.
14. Wardlaw JM, Marshall I, Wild J, Dennis MS, Cannon J, Lewis SC. Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome. Stroke 1998;29:1618-24.
15. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34:721-7.
16. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-61.
17. Balm R, van der Grond J, Mali WP, Eikelboom BC. Reestablishment of cerebral metabolism after carotid endarterectomy. Eur J Vasc Endovasc Surg 1995;10:182-6.
18. Matthews PM, Cianfaglia L, McLaurin J, et al. Demonstration of reversible decreases in N-acetylaspartate (NAA) in a neuronal cell line: NAA decreases as a marker of sublethal neuronal dysfunction [Abstract]. Proceedings of ISMRM 1995;1:147.
19. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylasparlale production: implications for 1H MRS studies in vivo. Neuroreport 1996;7:1397-400.
20. Cross JH, Connelly A, Jackson GD, Johnson CL, Neville BG, Gadian DG. Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy. Ann Neurol 1996;39:107-13.
21. Connelly A, Jackson GD, Duncan JS, King MD, Gadian DG. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 1994;44:1411-7.
22. Cendes F, Caramanos Z, Andermann F, Dubeau F, Arnold DL. Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol 1997;42:737-46.
23. Vermathen P, Ende G, Laxer KD, Knowlton RC, Maison GB, Weiner MW. Hippocampal N-acetylaspartate in neocortical epilepsy and mesial temporal lobe epilepsy. Ann Neuml 1997;42: 194-9.
24. Kuzniecky R, Hugg JW, Hetherington H, et al. Relative utility of 1IH spectroscopic imaging and hippocampal volumetry in the latralisation of mesial temporal lobe epilepsy. Neurology 1998;51: 66-71.
25. Ng TC, Comair YG, Xue M, et al. Temporal lobe epilepsy: presurgical localization with proton chemical shift imaging. Radiology 1994;193:464-72.
26. Connelly A, van Paesschen W, Porter DA, Johnson CL, Duncan JS, Gadian DG. Proton magnetic resonance spectroscopy in MRI-negative temporal lobe epilepsy. Neurology 1998:51:61-6.
27. Woermann FG, McLean MA, Bartlett PA, Parker GJ, Barker GJ, Duncan JS. Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol 1999;45:369-76.
28. Hugg JW, Kuzniecky RI, Gilliam FG, Morawetz RB, Fraught RE, Hetherington HP. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic-resonance spectroscopic imaging. Ann Neuml 1996;40:236-9.
29. Vermathen P, Ende G, Laxer KD, et al. 1H-MRSI follnw-up studies of epilepsy show strongly altered metabolite concentrations after surgery [Abstract]. Proceedings of ISMRM 1996;2:957.
30. Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997;49:1525-33.
31. Watson C, Moore GJ. Comparison of preoperative vs. postoperative 1H MR spectroscopic imaging findings in the contralateral temporal lobe following ipsilateral resection in adult temporal lobe epilepsy patients [Abstract]. Neurology 1998;50:A286.
32. Series W, Li LM, Cendes F, et al. Time course of postoperative NAA recovery in patients with intractable temporal lobe epilepsy [Abstract]. Neurology 1999;52:A18-A19.
33. Marson AG, Chadwick D. Comparing antiepileptic drugs. Curr Opin Neurol 1996;9:103-6.
34. Walker MC, Li LM. Sander JW. Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome [see comments]. Br Med J 1996;313:1184-5.
35. Tasch E, Cendes F, Li LM, Dubeau F, Andermann F, Arnold DL. Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy. Ann Neurol 1999;45:568-76.
36. Roth K, Kimber BJ. Feeney J Data shift accumulation and alternate delay accumulation techniques for overcoming dynamic range problems. J Magn Reson 1980;41:302-9.
37. Petroff OA, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn Reson Imaging 1995;13:1197-1211.
38. Hetherington H, Kuzniecky R, Pan J. et al. Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T. Ann Neurol 1995;38:396-404.
39. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-10.
40. van Paesschen W, Duncan JS, Stevens JM, Connelly A. Etiology and early prognosis of newly diagnosed partial seizures in adults: a quantitative hippocampal MRI study. Neurology 1997;49:753-7.
41. King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients [see comments]. Lancet 1998;352:1007-11.
42. Fernandez G, Effenberger O, Vinz B, et al. Hippocampal malformation as a cause of familial febrile convulsions and .subsequent hippocampal sclerosis [see comments]. Neurology 1998;50:909-17.
43. Germano IM, Sperber EF, Ahuja S, Moshe SL. Evidence of enhanced kindling and hippocampal neuronal injury in immature rats with neuronal migration disorders. Epilepsia 1998;39:1253-60.
44. Nguyen DK, Botez MI. Diaschisis and neurobehavior. Can J Neurol Sci 1998;25:5-12.
45. Rango M, Spagnoli D, Tomei G, Bamonti F, Scarlato G, Zetta L. Central nervous system trans-synaptic effects of acute axonal injury: a 1H magnetic resonance spectroscopy study. Magn Reson Med 1995;33:595-600.
46. Sato M, Racine RJ, McIntyre DC. Kindling: basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol 1990;76: 459-72.
47. Pilkanen A. Treatment with antiepileptic drugs: possible neuroprotective effects. Neurology 1996;47:12-6.
48. Halonen T, Nissinen J, Jansen JA, Pitkanen A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epileplicus. Eur J Pharmacol 1996;299:69-81.
49. Dalby NO, Nielsen EB. Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat. Neurosci Lett 1997;229:135-7.
50. Loscher W, Honack D, Rundteldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284: 474-9.
51. MacDonald RL, Greenfield LJ, Jr. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997;10:121-8.
52. Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-16.
53. Mendes-Ribeiro JA, Soares R, Simoes-Ribeiro F, Guimaraes ML. Reduction in temporal N-acetylaspartate and creatine (or choline) ratio in temporal lobe epilepsy: does this 1H-magnetic resonance spectroscopy finding mean poor seizure control? J Neurol Neurosurg Psychiatry 1998;65:518-22.
54. Gaillard WD, Weinstein S, Pearl PL, et al. Natural history of metabolic abnormalities in children with partial epilepsy determined by FDG-PET [Abstract]. Epilepsia 1998;39:101.
55. Leiderman DB, Albert P, Balish M, Bromfield E, Theodore WH. The dynamics of metabolic change following seizures as measured by positron emission tomography with fludeoxyglucose F 18. Arch Neurol 1994;51:932-6.
56. Cendes F, Stanley JA, Dubeau F, Andermann F, Arnold DL. Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures. Ann Neural 1997;41:74-81.